ALKBH5 and melanoma: Of note, the ALKBH5 gene mutation and expression status of ALKBH5 in melanoma tissues are highly correlated with the response to immunotherapy in patients, indicating that ALKBH5 is not only a therapeutic target but also a reliable biomarker in predicting the efficacy of immunotherapy (129).